Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotigotine Monotherapy Dose Escalation in Pediatric Idiopathic Restless Legs Syndrome
2014-004383-37Phase 2
- Sponsor
- UCB
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rotigotine in restless legs syndrome (RLS) (2 arms), sponsored by UCB. Primary endpoint: Apparent total body clearance (Cl/f) of unconjugated rotigotine.
02
Drugs
rotigotine
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on 2014-004383-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004383-37.